#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17454	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2073	835.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1703	1703	T	987	T,C	723,190	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17454	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2073	835.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1437	1437	C	1022	C	946	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31672	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3558	886.9	0	.	n	.	0	T695C	SNP	695	695	T	1080	1080	C	933	C,A,T	858,1,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31672	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3558	886.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1722	1722	A	1032	A,G	935,23	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31672	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3558	886.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2356	2356	C	1034	C	957	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31672	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3558	886.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2430	2430	A	1001	A	943	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31672	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3558	886.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2982	2982	C	975	C,A	907,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2206	folP	855	855	100.0	folP.l15.c4.ctg.1	1547	142.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1030	1032	AGC	228;225;228	A;G;C	215;210;212	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5682	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3401	166.5	1	SNP	p	S91F	1	.	.	271	273	TTC	544	546	TTC	186;187;188	T,G;T;C	168,1;168;168	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5682	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3401	166.5	1	SNP	p	G95N	0	.	.	283	285	GGC	556	558	GGC	192;193;192	G;G;C	179;178;177	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5682	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3401	166.5	1	SNP	p	D95G	1	.	.	283	285	GGC	556	558	GGC	192;193;192	G;G;C	179;178;177	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1844	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1318	138.8	1	SNP	p	G45D	0	.	.	133	135	GGC	540	542	GGC	226;227;230	G;G;C	209;208;211	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	948	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1086	86.8	0	.	n	.	0	A197.	DEL	197	197	A	568	568	A	218	A	204	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2941	203.6	1	SNP	p	D86N	0	.	.	256	258	GAC	520	522	GAC	252;250;250	G;A;C	234;225;232	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2941	203.6	1	SNP	p	S87R	1	.	.	259	261	CGT	523	525	CGT	249;249;250	C,A;G;T	231,1;228;231	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2941	203.6	1	SNP	p	R87I	0	.	.	259	261	CGT	523	525	CGT	249;249;250	C,A;G;T	231,1;228;231	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2941	203.6	1	SNP	p	R87W	0	.	.	259	261	CGT	523	525	CGT	249;249;250	C,A;G;T	231,1;228;231	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6014	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2941	203.6	1	SNP	p	S88P	0	.	.	262	264	TCC	526	528	TCC	249;248;247	T;C;C	230;231;228	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4762	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2464	191.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1457	1459	GGC	245;241;237	G;G;C	228;221;220	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1332	1334	GCA	244;243;243	G;C,T;A,C	221;220,1;227,1	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1335	1337	ATC	240;242;241	A;T,A;C,G	223;219,2;221,1	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1347	1349	GTG	241;242;243	G,A;T,C;G,C	221,1;218,1;224,1	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1347	1349	GTG	241;242;243	G,A;T,C;G,C	221,1;218,1;224,1	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1851	1853	ACC	243;247;247	A;C;C	219;226;223	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1905	1907	GCG	227;226;225	G;C;G	204;181;192	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1905	1907	GCG	227;226;225	G;C;G	204;181;192	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2028	2030	AGC	214;214;214	A,G;G;C,T	187,3;191;187,3	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2037	2039	GGC	208;207;204	G,A;G;C	177,4;181;178	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4484	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2420	182.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2055	2057	CCG	170;175;172	C,G;C;G	120,7;127;128	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6194	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3297	187.4	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1591	1593	ACG	227;226;224	A,G;C;G	195,6;203;199	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6194	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3297	187.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1729	1731	CCG	240;238;242	C;C;G	207;215;211	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2368	porA	1146	1146	99.91	porA.l15.c17.ctg.1	1752	133.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	602	602	C	155	C	140	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	355	357	GAA	247;245;246	G;A;A,G	235;233;236,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	643	645	GAT	295;296;296	G,A;A;T	276,5;282;283	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	766	768	TCA	284;287;288	T;C;A	268;270;272	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	895	897	GTC	248;248;247	G;T;C	233;229;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	0	.	p	.	0	F222S	NONSYN	664	666	TTT	907	909	TCT	251;254;255	T;C,T;T	236;238,3;243	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1225	1227	GCA	242;240;237	G;C,A;A	221;206,11;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	1	SNP	p	G120K	1	.	.	358	360	AAG	601	603	AAG	284;287;289	A;A;G	265;264;264	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	1	SNP	p	A121D	1	.	.	361	363	GAC	604	606	GAC	293;292;292	G,A;A;C	266,5;271;268	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3264	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1566	206.6	1	SNP	p	D121N	0	.	.	361	363	GAC	604	606	GAC	293;292;292	G,A;A;C	266,5;271;268	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12574	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4889	256.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1338	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1081	123.2	1	SNP	p	V57M	1	.	.	169	171	ATG	513	515	ATG	292;293;290	A;T;G	278;280;277	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
